Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Marian, Dmochowski"'
Autor:
Magdalena Jałowska, Monika Bowszyc-Dmochowska, Maciej Spałek, Bogusz Falkowski, Marian Dmochowski
Publikováno v:
Przegląd Dermatologiczny, Vol 110, Iss 6, Pp 689-693 (2024)
Externí odkaz:
https://doaj.org/article/104d5ba0476b46bb95bfd9b753e08aed
Publikováno v:
Przegląd Dermatologiczny, Vol 110, Iss 5, Pp 633-636 (2024)
Externí odkaz:
https://doaj.org/article/dbce73095df8439b9071a7b3e0f07c11
Autor:
Maciej Marek Spałek, Magdalena Jałowska, Natalia Welc, Monika Bowszyc-Dmochowska, Marian Dmochowski
Publikováno v:
Medicina, Vol 60, Iss 8, p 1324 (2024)
Background and Objectives: Dapsone (DP) is employed in the management of various skin conditions, including autoimmune bullous diseases to non-enzymes (n-eAIBDs). This study aimed to assess the advantages and safety profile of DP treatment in n-eAIBD
Externí odkaz:
https://doaj.org/article/fcd6149e114e431c958a4f58ffd390c0
Publikováno v:
Przegląd Dermatologiczny, Vol 110, Iss 1, Pp 12-22 (2023)
Bullous pemphigoid is an autoimmune blistering disease that very rarely affects children. Clinical differences in locations of skin lesions led to the distinction of infantile versus childhood pemphigoid. Mucous membranes can be affected. The first-l
Externí odkaz:
https://doaj.org/article/d69a6171bd4d4505baf851f2dd4afae7
Autor:
Magdalena Jałowska, Maciej Spałek, Monika Bowszyc-Dmochowska, Justyna Gornowicz- Porowska, Marian Dmochowski
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe involvement of palms and soles is variable among disease entities belonging to autoimmune bullous diseases (AIBD). We present our own clinical-laboratory experience concerning presentations of skin lesions on palms and soles in the pe
Externí odkaz:
https://doaj.org/article/94c1abc32d2140b5a85fd9acff8dab80
Publikováno v:
Medicina, Vol 60, Iss 2, p 270 (2024)
Background and Objectives: Rituximab (RTX) has been the predominant treatment for autoimmune bullous diseases (AIBDs). The objective of this research was to assess the advantages and safety characteristics of RTX treatment in individuals with AIBD. T
Externí odkaz:
https://doaj.org/article/0ac5f94d37e84212b6c7d8f87fecb75b
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
In this conceptual analysis, we present our concepts on two issues regarding autoimmune bullous diseases (AIBD), namely (i) current nomenclature of AIBD requires updating by incorporating molecular data and (ii) pemphigus vulgaris (PV) “likes” ar
Externí odkaz:
https://doaj.org/article/ed60c14744774040b43c04dda4c3fb49
Publikováno v:
Medicina, Vol 59, Iss 7, p 1265 (2023)
Background and Objectives: Autoimmune bullous diseases (AIBDs) may be treated with intravenous immunoglobulin (IVIG) infusions. This study aimed to evaluate the benefits and safety profiles of high-dose IVIG therapy in AIBD patients, as determined by
Externí odkaz:
https://doaj.org/article/53d0f31f032741d28f0a29fe87714e7f
Autor:
Magdalena Danuta Jałowska, Justyna Gornowicz-Porowska, Agnieszka Seraszek-Jaros, Monika Bowszyc-Dmochowska, Elżbieta Kaczmarek, Marian Dmochowski
Publikováno v:
Central European Journal of Immunology, Vol 46, Iss 2, Pp 183-190 (2021)
Externí odkaz:
https://doaj.org/article/01a54f6ee6364b76891dcb1d87a480dd
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Bullous pemphigoid (BP) is a cutaneous disease triggered by numerous stimuli, where genetic milieu-influenced autoimmunity to hemidesmosomal proteins, namely, BP180 and/or BP230 initiate an inflammation leading to dermal-epidermal junction (DEJ) enzy
Externí odkaz:
https://doaj.org/article/550b6587ad1743099d3911f716ddc3a7